Aktuelle Diagnostik und Therapie der pulmonalen Hypertonie

Zusammenfassung

Krankheitsverständnis und Therapie der pulmonalen Hypertonie haben sich in den letzten Jahren grundlegend gewandelt. Für die pulmonal arterielle Hypertonie stehen mittlerweile mit Endothelin-Rezeptor-Antagonisten, Phosphodiesterase-5-Inhibitoren und Prostanoiden drei wirksame Substanzklassen zu Verfügung. Gleichzeitig werden auch Therapieverfahren für andere Formen der pulmonalen Hypertonie entwickelt. Entsprechend wichtig sind heute ein möglichst frühzeitiges Erkennen einer pulmonalen Hypertonie sowie die korrekte diagnostische Klassifikation als Voraussetzung einer gezielten und effektiven Behandlung. Dieser Artikel beschreibt moderne diagnostische Strategien sowie aktuelle Therapieprinzipien für die aus Sicht des Pneumologen wichtigsten Formen der pulmonalen Hypertonie. Die anschließenden CME-Fragen beziehen sich ausschließlich auf praxisrelevante Inhalte.

Literatur

• 1 Galie N, Torbicki A, Barst R. et al . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
• 2 Chaouat A, Bugnet A S, Kadaoui N. et al . Severe pulmonary hypertension and chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2005;  172 189-194
• 3 Resten A, Maitre S, Humbert M. et al . Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease.  AJR Am J Roentgenol. 2004;  183 65-70
• 4 Rabiller A, Jais X, Hamid A. et al . Occult alveolar haemorrhage in pulmonary veno-occlusive disease.  Eur Respir J. 2006;  27 108-113
• 5 Sitbon O, Humbert M, Nunes H. et al . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788
• 6 Wensel R, Opitz C F, Anker S D. et al . Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.  Circulation. 2002;  106 319-324
• 7 Nagaya N, Nishikimi T, Uematsu M. et al . Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.  Circulation. 2000;  102 865-870
• 8 Leuchte H H, Holzapfel M, Baumgartner R A. et al . Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 764-770
• 9 Simonneau G, Galie N, Rubin L J. et al . Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 5S-12S
• 10 Sitbon O, Humbert M, Jais X. et al . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
• 11 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
• 12 Humbert M, Morrell N W, Archer S L. et al . Cellular and molecular pathobiology of pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43 13S-24S
• 13 Hoeper M M. Drug treatment of pulmonary arterial hypertension: current and future agents.  Drugs. 2005;  65 1337-1354
• 14 Farber H W, Loscalzo J. Pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1655-1665
• 15 Barst R J, Rubin L J, Long W A. et al . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med. 1996;  334 296-302
• 16 Hoeper M M, Spiekerkoetter E, Westerkamp V. et al . Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension.  Eur Respir J. 2002;  20 339-343
• 17 Gomberg-Maitland M, Tapson V F, Benza R L. et al . Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension.  Am J Respir Crit Care Med. 2005;  172 1586-1589
• 18 Olschewski H, Simonneau G, Galie N. et al . Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 19 Opitz C F, Wensel R, Winkler J. et al . Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.  Eur Heart J. 2005;  26 1895-1902
• 20 Channick R N, Simonneau G, Sitbon O. et al . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
• 21 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 22 Sitbon O, Gressin V, Speich R. et al . Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  170 1212-1217
• 23 Hoeper M M, Halank M, Marx C. et al . Bosentan therapy for portopulmonary hypertension.  Eur Respir J. 2005;  25 502-508
• 24 McLaughlin V V, Sitbon O, Badesch D B. et al . Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
• 25 Sitbon O, McLaughlin V V, Badesch D B. et al . Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.  Thorax. 2005;  60 1025-1030
• 26 Barst R J, Langleben D, Frost A. et al . Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
• 27 Galie N, Badesch D, Oudiz R. et al . Ambrisentan therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2005;  46 529-535
• 28 Galie N, Ghofrani H A, Torbicki A. et al . Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension.  N Engl J Med. 2005;  353 2148-2157
• 29 Hoeper M M, Welte T. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2006;  354 1091-1093; author reply 1091 - 1093
• 30 Ghofrani H A, Rose F, Schermuly R T. et al . Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
• 31 Hoeper M M, Faulenbach C, Golpon H. et al . Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
• 32 Hoeper M M, Taha N, Bekjarova A. et al . Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
• 33 Hoeper M M, Markevych I, Spiekerkoetter E. et al . Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.  Eur Respir J. 2005;  26 858-863
• 34 Scharf S M, Iqbal M, Keller C. et al . Hemodynamic characterization of patients with severe emphysema.  Am J Respir Crit Care Med. 2002;  166 314-322
• 35 Kessler R, Faller M, Weitzenblum E. et al . “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.  Am J Respir Crit Care Med. 2001;  164 219-224
• 36 Barbera J A, Peinado V I, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease.  Eur Respir J. 2003;  21 892-905
• 37 Weitzenblum E, Apprill M, Oswald M. et al . Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema.  Chest. 1994;  105 1377-1382
• 38 Agostoni P, Doria E, Galli C. et al . Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1989;  139 120-125
• 39 Nadrous H F, Pellikka P A, Krowka M J. et al . Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.  Chest. 2005;  128 2393-2399
• 40 Olschewski H, Ghofrani H A, Walmrath D. et al . Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.  Am J Respir Crit Care Med. 1999;  160 600-607
• 41 Ghofrani H A, Wiedemann R, Rose F. et al . Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.  Lancet. 2002;  360 895-900
• 42 Hoeper M M, Mayer E, Simonneau G. et al . Chronic thromboembolic pulmonary hypertension.  Circulation. 2006;  113 2011-2020
• 43 Dartevelle P, Fadel E, Mussot S. et al . Chronic thromboembolic pulmonary hypertension.  Eur Respir J. 2004;  23 637-648
• 44 Jamieson S W, Kapelanski D P, Sakakibara N. et al . Pulmonary endarterectomy: experience and lessons learned in 1,500 cases.  Ann Thorac Surg. 2003;  76 1457-1462; discussion 1462 - 1464
• 45 Ghofrani H A, Schermuly R T, Rose F. et al . Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.  Am J Respir Crit Care Med. 2003;  167 1139-1141
• 46 Hoeper M M, Kramm T, Wilkens H. et al . Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.  Chest. 2005;  128 2363-2367
• 47 Bonderman D, Nowotny R, Skoro-Sajer N. et al . Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.  Chest. 2005;  128 2599-2603
• 48 Hughes R, George P, Parameshwar J. et al . Bosentan in inoperable chronic thromboembolic pulmonary hypertension.  Thorax. 2005;  60 707